MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 12-16-2023
Covetrus Revenue 2011-2026 | CVET
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Covetrus
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.58 B | 4.34 B | 3.98 B | 3.78 B | 3.58 B | 3.35 B | 2.98 B | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.58 B | 2.98 B | 3.8 B |
Quarterly Revenue Covetrus
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 1.15 B | - | 1.16 B | 1.19 B | 1.1 B | 1.12 B | 1.13 B | 1.03 B | 1.06 B | 1.01 B | 1.02 B | 1.01 B | 941 M | 903 M | 923 M | 1 B | 947 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.19 B | 903 M | 1.04 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B |  USA |
 |
Computer Programs and Systems
CPSI
|
339 M | - | 4.4 % | $ 133 M | USA |
 |
Change Healthcare
CHNG
|
3.09 B | - | - | $ 9.03 B | USA |
 |
Accolade
ACCD
|
170 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
Evolent Health
EVH
|
382 M | $ 3.93 | 4.11 % | $ 368 M | USA |
 |
Akerna Corp.
KERN
|
20.5 M | - | - | $ 161 M | USA |
 |
Health Catalyst
HCAT
|
307 M | $ 2.2 | -4.76 % | $ 132 M | USA |
 |
HealthStream
HSTM
|
292 M | $ 21.27 | -2.48 % | $ 646 M | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.5 B | - | -10.39 % | $ 886 M | USA |
 |
HealthEquity
HQY
|
262 M | $ 84.42 | -1.11 % | $ 7.22 B | USA |
 |
American Well Corporation
AMWL
|
254 M | $ 4.64 | -2.52 % | $ 69.6 M | USA |
 |
MTBC
MTBC
|
111 M | - | -0.58 % | $ 51.7 M | USA |
 |
1Life Healthcare
ONEM
|
623 M | - | - | $ 3.37 B | USA |
 |
So-Young International
SY
|
-1.52 M | $ 2.69 | 0.56 % | $ 214 M |  China |
 |
GoodRx Holdings
GDRX
|
792 M | $ 2.6 | -3.17 % | $ 1 B | USA |
 |
OptimizeRx Corporation
OPRX
|
71.5 M | $ 11.92 | -1.89 % | $ 204 M | USA |
 |
Omnicell
OMCL
|
1.11 B | $ 49.14 | -2.73 % | $ 2.26 B | USA |
 |
Premier
PINC
|
263 M | - | - | $ 2.33 B | USA |
 |
Progyny
PGNY
|
298 M | $ 25.33 | 3.3 % | $ 2.17 B | USA |
 |
Phreesia
PHR
|
356 M | $ 15.64 | -4.58 % | $ 853 M | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
Zhongchao
ZCMD
|
16.3 M | $ 0.48 | -3.92 % | $ 2.5 M | China |
 |
Schrödinger
SDGR
|
208 M | $ 16.37 | -2.5 % | $ 1.19 B | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
NextGen Healthcare
NXGN
|
557 M | - | - | $ 1.6 B | USA |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
10x Genomics
TXG
|
619 M | $ 22.12 | 7.77 % | $ 2.59 B | USA |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
2.57 B | $ 6.08 | -3.18 % | $ 1.04 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
Veeva Systems
VEEV
|
2.36 B | $ 215.95 | -2.82 % | $ 34.7 B | USA |
 |
SCWorx Corp.
WORX
|
2.99 M | $ 0.18 | -2.23 % | $ 263 K | USA |